BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24166351)

  • 1. Hepatitis C virus genotype 1: how genetic variability of the core protein affects the response to pegylated-interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; Elhefnawi M; Zaid A; Al-Qahtani AA
    J Med Virol; 2014 Feb; 86(2):224-34. PubMed ID: 24166351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
    Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
    Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variability of the core protein in hepatitis C virus genotype 4 in Saudi Arabian patients and its implication on pegylated interferon and ribavirin therapy.
    Alhamlan FS; Al-Ahdal MN; Khalaf NZ; Abdo AA; Sanai FM; Al-Ashgar HI; ElHefnawi M; Zaid A; Al-Qahtani AA
    J Transl Med; 2014 Apr; 12():91. PubMed ID: 24708767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2011 Jun; 83(6):1016-22. PubMed ID: 21503914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
    Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral decline over 48h and HCV amino acid mutations are related to efficacy of PEG-IFN/ribavirin.
    Miyasaka A; Kumagai I; Abe K; Suzuki K
    Hepatogastroenterology; 2012 May; 59(115):794-9. PubMed ID: 22020909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus amino acid sequence diversity correlates with the outcome of combined interferon/ribavirin therapy in Chinese patients with chronic hepatitis C.
    Zeng Y; Li W; Li J; Wang J; Zhou B; Zhang J; Liu S; Wu Y; Hou J; Zhou Y
    Arch Virol; 2012 Jun; 157(6):1113-21. PubMed ID: 22426896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2009 Jun; 81(6):1032-9. PubMed ID: 19382270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1B.
    Murayama M; Katano Y; Nakano I; Ishigami M; Hayashi K; Honda T; Hirooka Y; Itoh A; Goto H
    J Med Virol; 2007 Jan; 79(1):35-40. PubMed ID: 17133546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of amino acid variations in the NS3, NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy.
    Chusri P; Kumthip K; Pantip C; Thongsawat S; O'Brien A; Maneekarn N
    Virus Res; 2015 Jan; 196():37-43. PubMed ID: 25445343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Core amino acid variation at position 110 is associated with sustained virological response in Caucasian patients with chronic hepatitis C virus 1b infection.
    Di Lello FA; Mira JA; Neukam K; Parra-Sánchez M; Guelfo JR; Cifuentes C; Macías J; Palomares JC; Gómez-Mateos J; Pineda JA; Real LM
    Arch Virol; 2014 Dec; 159(12):3345-51. PubMed ID: 25161034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
    Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
    J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
    Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.
    El-Shamy A; Shoji I; El-Akel W; Bilasy SE; Deng L; El-Raziky M; Jiang DP; Esmat G; Hotta H
    J Clin Microbiol; 2012 Dec; 50(12):3886-92. PubMed ID: 22993188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.
    Kurbanov F; Tanaka Y; Matsuura K; Sugauchi F; Elkady A; Khan A; Hasegawa I; Ohno T; Tokuda H; Mizokami M
    J Infect Dis; 2010 Jun; 201(11):1663-71. PubMed ID: 20420509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
    Zeng Y; Kang Y; Shang J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):401-6. PubMed ID: 25203700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    Hepatology; 2007 Nov; 46(5):1357-64. PubMed ID: 17657816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.